Skip to main content

CCTG Publications

CCTG Publications

Canadian Cancer Trials Group Publications

As information about published study results becomes known, it will be available via the links below and announced in the CCTG Connection Newsletter. Both Canadian Cancer Trials Group and Intergroup led trials for which there has been at least one publication are included. If you do not find a particular study, this is likely because the final results are not yet available since many of our studies follow the health of participants for several years. We also suggest using PubMed, a free searchable database of research citations and abstracts.

Network members

If you are looking for a specific CCTG trial please refer to the study's protocol and informed consent document or visit http://www.clinicaltrials.gov for further information about when the final study results are likely expected. Share any information with investigators at your institution and the study participants at your centre so they may be informed of results. Please ensure all local policies regarding dissemination of clinical trial results to staff and patients are followed. 

We are indebted to trial participants, physicians and other health care professionals who have contributed to the successful completion of hundreds of Canadian Cancer Trials Group trials.

For the most recent conference presentations and abstracts please visit Conference Presentations >

Publications

A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: results of the international IROCAS study (ONLINE)Annals of Oncology

Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (Alliance) (Online)JNCI Cancer Spectrum

Discrepancy between MRI Reading Following Diagnostic LEEP/Cone and Final Pathology of the Hysterectomy Specimen; An Exploratory Analysis from the CCTG CX.5/SHAPE TrialInternational Gynecological Cancer Society

Stratification of Vulvar Squamous Cell Carcinoma (VSCC) By HPV And P53 Status to Guide Excision: CCTG VU.2 STRIVE Study (NCT06358469)International Gynecological Cancer Society

Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505) (Online)Journal of Clinical Oncology

The UVA-induced single-base mutational signature of CX-5461 in human cellsNucleic Acids Research

Enhancing Radiotherapy Clinical Trial Follow-Up through Linked Administrative Data: A Canadian Cancer Trials Group (CCTG) Pilot Study of the SC.24 Randomized Trial of Stereotactic Body Radiotherapy for Painful Spinal MetastasisCanadian Association of Radiation Oncology

Establishment of harmonized international reference ranges for plasma estradiol concentrations in postmenopausal womenThe Journal of Clinical Endocrinology & Metabolism

PR22 findings were presented by Dr. Tamim Niazi at the Presidential Symposium at European Society for Medical Oncology (ESMO) 2026 Congress.

Early findings from the PR.22 trial show promise in delaying the spread of high-risk prostate cancer

Interim results from the CCTG PR.22 (DASL-HiCaP ANZUP 1801) clinical trial, has seen a delay in the spread of prostate cancer. The findings were presented by Dr. Tamim Niazi at the Presidential Symposium at European Society for Medical Oncology (ESMO) 2026 Congress. “Early results indicate that intensifying standard radiation and hormone therapy with Darolutamide may decrease the risk of metastatic spread in prostate cancer patients at higher risk of disease recurrence or progression,” says Dr. Tamim Niazi, the DASL-HiCaP study co-chair and Radiation Oncologist at Jewish General Hospital. “If supported by longer-term data, this approach offers a meaningful opportunity to extend the time patients live without cancer progression.”

More >>
 
The final analysis of the HN9 trial shows that new immunotherapy treatment did not improve event free survival

HN9 final analysis shows that new immunotherapy treatment did not improve event free survival

Final results from the CCTG HN.9 (EORTC 1740-HNCG) were presented at ASCO 2026, highlighting the challenges of reducing treatment intensity while maintaining outcomes for oropharyngeal cancer patients .

More >>
 
PR21 Secondary Analysis Explores Treatment Sequencing in Advanced Prostate Cancer Trial

PR21 Secondary Analysis Explores Treatment Sequencing in Advanced Prostate Cancer

Results from a pre-planned secondary analysis of the PR21 PLUDO trial were presented at ASCO 2026—providing insight into treatment sequencing for patients with metastatic castration-resistant prostate cancer (mCRPC). 

More >>
 
Dr Nappi on stage at ASCO 2026 presenting interim results for CCTG trial

A simple blood test may detect tumor relapse in patients with early-stage germ cell tumors

The interim results of the GCC.1 (S1823) study were presented at ASCO 2026 during the Genitourinary Cancer Session. The study focuses on patients with early-stage germ cell tumors and the blood biomarker microribonucleic acid (miRNA) 371a-3p (called miR371). The presence of miR371 may allow clinicians to identify patients at higher risk of relapse earlier and more accurately than current monitoring approaches.

More >>